Skip to content

Transitional Care Study 3

PJ-013483 FLAGSHIP Transitional Care Study 3

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03923127
Acronym
TRICA
Enrollment
350
Registered
2019-04-22
Start date
2019-04-16
Completion date
2020-08-17
Last updated
2020-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery--Complications

Brief summary

In this study patients with elective surgery will wear two devices (HealthDot and Elan) after surgery in hospital and after discharge at home for up to 2 weeks (HealthDot) or 3 weeks (Elan). The HealthDot will measure heart rate, posture, activity and respiratory rate which are stored on the device as well as sent to Philips. The Elan device will measure PPG and accelerometer data which is transferred to Philips. The data collected will be used for algorithm development. Data will be analysed retrospectively and compared to readmission and adverse events to see if the events could have been predicted due to the collected data by the devices. No clinical decisions will be based on the measurements done during the study.

Interventions

OTHERElan and HealthDot

Patients with elective surgery will wear two devices (HealthDot and Elan) after surgery in hospital and after discharge at home for up to 2 weeks (HealthDot) or 3 weeks (Elan).

Sponsors

Philips Electronics Nederland B.V. acting through Philips CTO organization
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Adult * Willing and able to sign informed consent form * Willingness to abstain from visiting a sauna during the study period * Willingness to dry area where the HealthDot is applied in a dipping fashion after washing * Willingness to abstain from flying during the study period of time * Elective surgery * General anesthesia required for surgery

Exclusion criteria

* General inmates of psychiatric wards, prisons, or other state institutions * Investigator or any other team member involved directly or indirectly in the conduct of the clinical study * Any skin condition, for example prior rash, discoloration, scars or open wounds at the area of investigation of both devices * Pregnant, or breastfeeding * Known to be allergic for the tissue adhesive used in the HealthDot. * Use of topical that is known to influence the skin at the test area (such as medical and non-medical creams or lotions) * Patient with active implantables such as Implantable Cardioverter Defibrilator (ICD) and pacemaker * Unable to understand instructions * Expected participation less than 2 weeks * Left lower rib (place where HealthDot will be applied) is involved in the area of surgery, area of disinfection or area where bandages are needed. * Area on arm where the Elan device is applied is involved in the surgical procedure. * Patients with antibiotic resitant infections (e.g. MRSA).

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity and specificity3 weeksEvaluate the sensitivity and specificity for the prediction of deterioration after surgery using the data from both devices.

Secondary

MeasureTime frameDescription
Accuracy HealthDot2 weeksEvaluate if the calculated heart rate and respiratory rate data collected by HealthDot are accurate compared to a gold standard as used in the hospital
Comfort of wearing measured by questionnaireat week 2Comfort of wearing the HealthDot will be assessed by VAS scale 1-10 while 1 beeing very comfortable, and 10 very uncomfortable
Accuracy Elan3 weeksEvaluate if the calculated heart rate and respiratory rate data collected by Elan are accurate compared to a gold standard as used in the hospital

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026